WO2019020831A1 - AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES - Google Patents
AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES Download PDFInfo
- Publication number
- WO2019020831A1 WO2019020831A1 PCT/EP2018/070533 EP2018070533W WO2019020831A1 WO 2019020831 A1 WO2019020831 A1 WO 2019020831A1 EP 2018070533 W EP2018070533 W EP 2018070533W WO 2019020831 A1 WO2019020831 A1 WO 2019020831A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bond
- oligo
- conjugate
- acid
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CN*[Si](*)(F)S Chemical compound CN*[Si](*)(F)S 0.000 description 4
- KBMJSJLUSFSZDF-UDJXWAEYSA-N CC(C)(C)[Si+](C(C)(C)C)(c(cc1)ccc1C(NC(CNC(CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)C(NC(CCCCNC(CCC(NCCCC(C(O)O)NC(CC[C@@H](C(O)=O)NC(N[C@@H](CCC(O)=O)C(O)=O)=O)=O)=O)=O)C(O)=O)=O)=O)F Chemical compound CC(C)(C)[Si+](C(C)(C)C)(c(cc1)ccc1C(NC(CNC(CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)C(NC(CCCCNC(CCC(NCCCC(C(O)O)NC(CC[C@@H](C(O)=O)NC(N[C@@H](CCC(O)=O)C(O)=O)=O)=O)=O)=O)C(O)=O)=O)=O)F KBMJSJLUSFSZDF-UDJXWAEYSA-N 0.000 description 1
- LEQUQDHPRFLVNZ-UHFFFAOYSA-O CC(C)(C)[Si+](C(C)(C)C)(c(cc1)ccc1C(NCC(C(NC(CCCCNC(CCC(NCCCC(C(O)=O)NC(CCC(C(O)=O)NC(NC(CCC(O)=O)C(O)=O)=O)=O)=O)=O)C(O)=O)=O)N(C=C(CNC(CCP(CN1CCN(CP(CCC(O)=O)(O)=O)CCN(CP(CCC(O)=O)(O)=O)CC1)(O)=O)=O)N)[NH2+]C)=O)F Chemical compound CC(C)(C)[Si+](C(C)(C)C)(c(cc1)ccc1C(NCC(C(NC(CCCCNC(CCC(NCCCC(C(O)=O)NC(CCC(C(O)=O)NC(NC(CCC(O)=O)C(O)=O)=O)=O)=O)=O)C(O)=O)=O)N(C=C(CNC(CCP(CN1CCN(CP(CCC(O)=O)(O)=O)CCN(CP(CCC(O)=O)(O)=O)CC1)(O)=O)=O)N)[NH2+]C)=O)F LEQUQDHPRFLVNZ-UHFFFAOYSA-O 0.000 description 1
- IZILOAUYUBWZKM-NQHNRGARSA-N CC(C)(C)[Si+](C(C)(C)C)(c(cc1)ccc1C(NCC(C(NC(CCCCNC(CCC(NCCCC(C(O)=O)NC(CC[C@@H](C(O)=O)NC(N[C@@H](CCC(O)=O)C(O)=O)=O)=O)=O)=O)C(O)=O)=O)NC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)=O)F Chemical compound CC(C)(C)[Si+](C(C)(C)C)(c(cc1)ccc1C(NCC(C(NC(CCCCNC(CCC(NCCCC(C(O)=O)NC(CC[C@@H](C(O)=O)NC(N[C@@H](CCC(O)=O)C(O)=O)=O)=O)=O)=O)C(O)=O)=O)NC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)=O)F IZILOAUYUBWZKM-NQHNRGARSA-N 0.000 description 1
- PWTSPEGACSAOPW-OKTBSVBZSA-N CC(C)(C)[Si+](C(C)(C)C)(c(cc1)ccc1C(NCC(C(NC(CCCCNC(CCCCCCC(NCCCC[C@@H](C(O)=O)NC(NC(CCC(O)=O)C(O)=O)=O)=O)=O)C(O)=O)=O)NC(CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)=O)F Chemical compound CC(C)(C)[Si+](C(C)(C)C)(c(cc1)ccc1C(NCC(C(NC(CCCCNC(CCCCCCC(NCCCC[C@@H](C(O)=O)NC(NC(CCC(O)=O)C(O)=O)=O)=O)=O)C(O)=O)=O)NC(CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)=O)F PWTSPEGACSAOPW-OKTBSVBZSA-N 0.000 description 1
- FTOTTWFWDIPGIE-VWYCJHECSA-N CCCC[C@H](C(O)=O)NC(CC[C@@H](C(O)=O)NC(N[C@@H](CCC(O)=O)C(O)=O)=O)=O Chemical compound CCCC[C@H](C(O)=O)NC(CC[C@@H](C(O)=O)NC(N[C@@H](CCC(O)=O)C(O)=O)=O)=O FTOTTWFWDIPGIE-VWYCJHECSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- ligands which are capable of binding to a disease-relevant target molecule may be cyclic peptides, such cyclic peptides are not chelating groups as envisaged herein, as the problem of the hydrophobic SIFA moiety is not solved in the absence of a further chelating moiety.
- compounds of the invention require a hydrophilic chelating group in addition to the ligands which are capable of binding to a disease-relevant target molecule.
- the hydrophilic chelating group is required to reduce the hydrophobic nature of the compounds caused by the presence of the SIFA moiety.
- radiopharmaceuticals and/or diagnostics according to the invention can be directly compared and thus will allow to link such data (e.g. data from a center in Europe working with F-18 and another center in India working with Ga-68).
- logP value (sometimes also referred to as logD value) is an art-established measure.
- the present disclosure furthermore relates to the following items.
- a macrocyclic ring structure with 8 to 20 ring atoms of which 2 or more, preferably 3 or more, are selected from oxygen atoms and nitrogen atoms;
- R 1L is CH 2 , NH or O, preferably NH;
- R 11 to R 15 are independently selected from C2 to C8 alkylene, preferably linear C2 to C8 alkylene.
- PET data (90 min acquisition time, OSEM 3D reconstruction) in blood pool (heart), muscle, kidneys, liver and LNCaP tumor xenograft of 68 Ga- nat F -8 in a
- Figure 27 Set of images of an 80 year old patient with progressive advanced castration resistant prostate cancer (PSA 66.4 ng/ml). Images shows high uptake of 18F- labelled PSMA-SIFA3 (7) in different classes of prostate cancer lesions (local tumor, lymph node metastases, bone metastases, liver metastases). Lesions demonstrated are as small as 2 mm (arrows indicate representative, not all tumor lesions).
- a proof-of-concept evaluation of use in humans was conducted under compassionate use.
- the agent was applied in compliance with The German Medicinal Products Act, AMG ⁇ 13 2b, and in accordance with the responsible regulatory body (Government of Oberbayern).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine (AREA)
Priority Applications (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020247006169A KR20240027896A (ko) | 2017-07-28 | 2018-07-30 | 이중 모드 방사성 트레이서 및 치료법 |
| FIEP18743540.9T FI3658194T3 (fi) | 2017-07-28 | 2018-07-30 | Dual mode -radiomerkkiaine ja -terapia |
| KR1020207005589A KR102752620B1 (ko) | 2017-07-28 | 2018-07-30 | 이중 모드 방사성 트레이서 및 치료법 |
| IL318092A IL318092A (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and –therapeutics |
| MX2020000352A MX2020000352A (es) | 2017-07-28 | 2018-07-30 | Marcador radioactivo de modo dual y terapeuticos. |
| JP2020526688A JP7059372B2 (ja) | 2017-07-28 | 2018-07-30 | デュアルモードの放射性トレーサーおよび療法剤 |
| BR112020001785-0A BR112020001785A2 (pt) | 2017-07-28 | 2018-07-30 | radiotraçador e compostos radioterapêuticos bimodais |
| IL272291A IL272291B2 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
| CA3071315A CA3071315A1 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
| PL18743540.9T PL3658194T3 (pl) | 2017-07-28 | 2018-07-30 | Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania |
| ES18743540T ES3011272T3 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
| EP22150556.3A EP4000640A1 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and therapeutic |
| US16/634,759 US11413360B2 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and—therapeutics |
| AU2018308699A AU2018308699B2 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
| CN201880062949.0A CN111132700B (zh) | 2017-07-28 | 2018-07-30 | 双模放射性示踪剂与治疗剂 |
| EA202090370A EA202090370A1 (ru) | 2017-07-28 | 2018-07-30 | Двухрежимная радиоактивная метка и радиотерапевтическое средство |
| DK18743540.9T DK3658194T3 (da) | 2017-07-28 | 2018-07-30 | Kombineret radiotracer og -terapeutika |
| EP24184312.7A EP4424378A3 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
| EP18743540.9A EP3658194B1 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
| SG11202000725WA SG11202000725WA (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
| ZA2020/00467A ZA202000467B (en) | 2017-07-28 | 2020-01-23 | Dual mode radiotracer and -therapeutics |
| JP2022065524A JP2022101601A (ja) | 2017-07-28 | 2022-04-12 | デュアルモードの放射性トレーサーおよび療法剤 |
| US17/849,297 US12390540B2 (en) | 2017-07-28 | 2022-06-24 | Dual mode radiotracer and -therapeutics |
| AU2024200440A AU2024200440B2 (en) | 2017-07-28 | 2024-01-24 | Dual mode radiotracer and -therapeutics |
| US18/948,808 US12453787B2 (en) | 2017-07-28 | 2024-11-15 | Dual mode radiotracer and-therapeutics |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17183795.8 | 2017-07-28 | ||
| EP17183795 | 2017-07-28 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/634,759 A-371-Of-International US11413360B2 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and—therapeutics |
| US17/849,297 Continuation US12390540B2 (en) | 2017-07-28 | 2022-06-24 | Dual mode radiotracer and -therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019020831A1 true WO2019020831A1 (en) | 2019-01-31 |
Family
ID=59501286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2018/070533 Ceased WO2019020831A1 (en) | 2017-07-28 | 2018-07-30 | AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11413360B2 (enExample) |
| EP (3) | EP3658194B1 (enExample) |
| JP (2) | JP7059372B2 (enExample) |
| KR (2) | KR102752620B1 (enExample) |
| CN (1) | CN111132700B (enExample) |
| AU (2) | AU2018308699B2 (enExample) |
| BR (1) | BR112020001785A2 (enExample) |
| CA (1) | CA3071315A1 (enExample) |
| DK (1) | DK3658194T3 (enExample) |
| EA (1) | EA202090370A1 (enExample) |
| ES (1) | ES3011272T3 (enExample) |
| FI (1) | FI3658194T3 (enExample) |
| HU (1) | HUE070098T2 (enExample) |
| IL (2) | IL318092A (enExample) |
| MX (2) | MX2020000352A (enExample) |
| PL (1) | PL3658194T3 (enExample) |
| PT (1) | PT3658194T (enExample) |
| SG (1) | SG11202000725WA (enExample) |
| WO (1) | WO2019020831A1 (enExample) |
| ZA (1) | ZA202000467B (enExample) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020157184A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Cancer diagnostic imaging agents |
| WO2020157128A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof |
| WO2020157177A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| CN112168978A (zh) * | 2019-07-03 | 2021-01-05 | 北京大学 | 一种抗体偶联药物及其药物组合物与应用 |
| GB202108779D0 (en) | 2021-06-18 | 2021-08-04 | Blue Earth Diagnostics Ltd | Si-at therapeutic/diagnostic compounds |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| WO2021175147A1 (zh) * | 2020-03-02 | 2021-09-10 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| WO2021205185A1 (en) | 2020-04-09 | 2021-10-14 | Blue Earth Diagnostics Ltd | Pharmaceutical formulations |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| WO2022018264A1 (en) | 2020-07-23 | 2022-01-27 | Technische Universität München | Silicon-containing ligand compounds |
| CN114671806A (zh) * | 2022-04-08 | 2022-06-28 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
| EP4023250A1 (en) | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| WO2022171901A1 (en) | 2021-02-15 | 2022-08-18 | Technische Universität München | Dual mode radiotracer and therapeutics |
| WO2022238553A1 (en) * | 2021-05-14 | 2022-11-17 | Technische Universität München | Radiopharmaceutical somatostatin receptor ligands and precursors thereof |
| WO2023012282A1 (en) * | 2021-08-05 | 2023-02-09 | Technische Universität München | Ligand compounds comprising a chelating group as a bridging group |
| WO2023223050A1 (en) | 2022-05-19 | 2023-11-23 | Blue Earth Diagnostics Limited | Synthesis of fluorosilyl compounds |
| EP4041213A4 (en) * | 2019-10-29 | 2023-12-27 | The Cleveland Clinic Foundation | CONTRAST AGENTS DIRECTED AGAINST PSMA |
| WO2024023332A1 (en) | 2022-07-29 | 2024-02-01 | Technische Universität München | Silicon-based fluoride acceptor groups for radiopharmaceuticals |
| WO2024061483A1 (en) * | 2022-09-20 | 2024-03-28 | Technische Universität München | Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy |
| US12102696B2 (en) | 2020-09-03 | 2024-10-01 | Curium US, LLC | Radiolabeling and formulation for scale up of 64Cu-DOTATATE |
| US20250121102A1 (en) * | 2017-07-28 | 2025-04-17 | Technische Universität München | Dual mode radiotracer and-therapeutics |
| WO2025087896A1 (en) | 2023-10-24 | 2025-05-01 | Blue Earth Therapeutics Limited | Therapeutic combination |
| CN115484992B (en) * | 2020-04-09 | 2026-01-02 | 蓝地诊断有限公司 | Pharmaceutical preparation |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024054226A1 (en) * | 2022-09-06 | 2024-03-14 | Hoang Ba Xuan | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| JP2025539087A (ja) * | 2022-11-14 | 2025-12-03 | アクティス オンコロジー， インコーポレイテッド | 腎臓におけるミニタンパク質の減少された保持 |
| WO2025072791A2 (en) | 2023-09-29 | 2025-04-03 | Aktis Oncology, Inc. | Miniproteins, conjugates & uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626522A (zh) * | 2012-04-12 | 2012-08-08 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001346A1 (en) * | 1993-06-30 | 1995-01-12 | Akzo Nobel N.V. | Chelating compounds |
| CA2455598A1 (en) | 2001-07-27 | 2003-02-13 | Targesome, Inc. | Lipid constructs as therapeutic and imaging agents |
| AU2015273934B2 (en) * | 2014-06-10 | 2020-08-20 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| WO2016062370A1 (en) | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US20160287730A1 (en) * | 2015-03-31 | 2016-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Labeled evans blue dye derivative for in vivo serum albumin labeling |
| US10800797B2 (en) * | 2015-05-26 | 2020-10-13 | California Institute Of Technology | Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same |
| US11413360B2 (en) | 2017-07-28 | 2022-08-16 | Technische Universität München | Dual mode radiotracer and—therapeutics |
| WO2019115547A1 (en) * | 2017-12-11 | 2019-06-20 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| IL303420A (en) | 2019-01-30 | 2023-08-01 | Univ Muenchen Tech | Diagnostic imaging materials for cancer |
| AU2020213678B2 (en) | 2019-01-30 | 2024-05-30 | Technische Universität München | PSMA binding dual mode radiotracer and therapeutic |
-
2018
- 2018-07-30 US US16/634,759 patent/US11413360B2/en active Active
- 2018-07-30 PL PL18743540.9T patent/PL3658194T3/pl unknown
- 2018-07-30 MX MX2020000352A patent/MX2020000352A/es unknown
- 2018-07-30 IL IL318092A patent/IL318092A/en unknown
- 2018-07-30 WO PCT/EP2018/070533 patent/WO2019020831A1/en not_active Ceased
- 2018-07-30 EA EA202090370A patent/EA202090370A1/ru unknown
- 2018-07-30 SG SG11202000725WA patent/SG11202000725WA/en unknown
- 2018-07-30 IL IL272291A patent/IL272291B2/en unknown
- 2018-07-30 PT PT187435409T patent/PT3658194T/pt unknown
- 2018-07-30 ES ES18743540T patent/ES3011272T3/es active Active
- 2018-07-30 BR BR112020001785-0A patent/BR112020001785A2/pt unknown
- 2018-07-30 CN CN201880062949.0A patent/CN111132700B/zh active Active
- 2018-07-30 FI FIEP18743540.9T patent/FI3658194T3/fi active
- 2018-07-30 HU HUE18743540A patent/HUE070098T2/hu unknown
- 2018-07-30 JP JP2020526688A patent/JP7059372B2/ja active Active
- 2018-07-30 DK DK18743540.9T patent/DK3658194T3/da active
- 2018-07-30 EP EP18743540.9A patent/EP3658194B1/en active Active
- 2018-07-30 AU AU2018308699A patent/AU2018308699B2/en active Active
- 2018-07-30 EP EP24184312.7A patent/EP4424378A3/en active Pending
- 2018-07-30 EP EP22150556.3A patent/EP4000640A1/en not_active Withdrawn
- 2018-07-30 CA CA3071315A patent/CA3071315A1/en active Pending
- 2018-07-30 KR KR1020207005589A patent/KR102752620B1/ko active Active
- 2018-07-30 KR KR1020247006169A patent/KR20240027896A/ko not_active Ceased
-
2020
- 2020-01-10 MX MX2023007914A patent/MX2023007914A/es unknown
- 2020-01-23 ZA ZA2020/00467A patent/ZA202000467B/en unknown
-
2022
- 2022-04-12 JP JP2022065524A patent/JP2022101601A/ja active Pending
- 2022-06-24 US US17/849,297 patent/US12390540B2/en active Active
-
2024
- 2024-01-24 AU AU2024200440A patent/AU2024200440B2/en active Active
- 2024-11-15 US US18/948,808 patent/US12453787B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626522A (zh) * | 2012-04-12 | 2012-08-08 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
Non-Patent Citations (36)
| Title |
|---|
| AFSHAR-OROMIEH ET AL., EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 42, 2015, pages 197 - 209 |
| BARINKA ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, 2008, pages 7737 - 7743 |
| BENESOVA ET AL., JOURNAL OF NUCLEAR MEDICINE, vol. 56, 2015, pages 914 - 920 |
| BERNARD-GAUTHIER ET AL., BIOMED RES INT., vol. 2014, 2014, pages 454503 |
| CARDINALE ET AL., JOURNAL OF NUCLEAR MEDICINE: OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE, vol. 58, 2017, pages 425 - 431 |
| DIETLEIN ET AL., MOLECULAR IMAGING AND BIOLOGY, vol. 17, 2015, pages 575 - 584 |
| EDER ET AL., BIOCONJUGATE CHEMISTRY, vol. 23, 2012, pages 688 - 697 |
| GIESEL ET AL., EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 43, 2016, pages 1929 - 1930 |
| GIESEL ET AL., EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 44, 2017, pages 678 - 688 |
| KIESS ET AL., THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 59, 2015, pages 241 |
| LINDNER ET AL., BIOCONJUGATE CHEMISTRY, vol. 25, 2014, pages 738 - 749 |
| LINDNER S. ET AL., BIOCONJUG CHEM., vol. 25, no. 4, 16 April 2014 (2014-04-16), pages 738 - 49 |
| LIU ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, 2011, pages 7013 - 7016 |
| LOVKOVA ET AL., CHEMISTRY, vol. 15, 2009, pages 2140 - 7 |
| MACHULKIN ET AL., JOURNAL OF DRUG TARGETING, vol. 1-15, 2016 |
| MAURER ET AL., NATURE REVIEWS UROLOGY, 2016 |
| NIEDERMOSER S. ET AL., J NUCL MED., vol. 56, no. 7, July 2015 (2015-07-01), pages 1100 - 5 |
| NOTNI ET AL., CHEMISTRY, vol. 16, 2010, pages 7174 - 85 |
| NOTNI ET AL., EJNMMI RESEARCH, vol. 28, 2012 |
| REICH ET AL., CHEMICAL COMMUNICATIONS, vol. 53, 2017, pages 2586 - 2589 |
| ROBU ET AL., JOURNAL OF NUCLEAR MEDICINE, JNUMED., vol. 116.1789, 2016 |
| ROWE ET AL., MOLECULAR IMAGING AND BIOLOGY, 2016, pages 1 - 9 |
| ROWE ET AL., PROSTATE CANCER AND PROSTATIC DISEASES, 2016 |
| S. LITAU ET AL: "Next Generation of SiFA lin -Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics", BIOCONJUGATE CHEMISTRY, vol. 26, no. 12, 16 December 2015 (2015-12-16), pages 2350 - 2359, XP055452403, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00510 * |
| SANGSTER: "Octanol-water Partition Coefficients: fundamentals and physical chemistry", 1997, JOHN WILEY & SONS |
| SCHIRRMACHER E. ET AL., BIOCONJUGATE CHEM., vol. 18, 2007, pages 2085 - 2089 |
| SILVER ET AL., CLINICAL CANCER RESEARCH, vol. 3, 1997, pages 81 - 85 |
| SIMON LINDNER ET AL: "Synthesis and in Vitro and in Vivo Evaluation of SiFA-Tagged Bombesin and RGD Peptides as Tumor Imaging Probes for Positron Emission Tomography", BIOCONJUGATE CHEMISTRY, vol. 25, no. 4, 16 April 2014 (2014-04-16), pages 738 - 749, XP055449461, ISSN: 1043-1802, DOI: 10.1021/bc400588e * |
| VADIM BERNARD-GAUTHIER ET AL: "From Unorthodox to Established: The Current Status of 18 F-Trifluoroborate- and 18 F-SiFA-Based Radiopharmaceuticals in PET Nuclear Imaging", BIOCONJUGATE CHEMISTRY, vol. 27, no. 2, 17 February 2016 (2016-02-17), pages 267 - 279, XP055305200, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00560 * |
| WANGLER C. ET AL., BIOCONJUG CHEM., vol. 21, no. 12, 15 December 2010 (2010-12-15), pages 2289 - 96 |
| WANGLER C. ET AL., BIOCONJUGATE CHEM., vol. 20, no. 2, 2009, pages 317 - 321 |
| WANGLER ET AL., NAT PROTOC, vol. 7, 2012, pages 1946 - 55 |
| WEINEISEN ET AL., EJNMMI RESEARCH, vol. 4, 2014, pages 63 |
| WEINEISEN ET AL., JOURNAL OF NUCLEAR MEDICINE, vol. 55, 2014, pages 1083 - 1083 |
| ZHANG ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, 2010, pages 12711 - 12716 |
| ZHOU ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 4, 2005, pages 1015 - 1026 |
Cited By (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250121102A1 (en) * | 2017-07-28 | 2025-04-17 | Technische Universität München | Dual mode radiotracer and-therapeutics |
| US12453787B2 (en) * | 2017-07-28 | 2025-10-28 | Technische Universität München and Technische Universität München—Klinikum Rechts der Isar | Dual mode radiotracer and-therapeutics |
| US12390540B2 (en) | 2017-07-28 | 2025-08-19 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| AU2020213892B2 (en) * | 2019-01-30 | 2025-04-10 | Technische Universität München | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof |
| WO2020157177A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| AU2020213678B2 (en) * | 2019-01-30 | 2024-05-30 | Technische Universität München | PSMA binding dual mode radiotracer and therapeutic |
| US12377176B2 (en) | 2019-01-30 | 2025-08-05 | Technische Universität München | Cancer diagnostic imaging agents |
| JP7549585B2 (ja) | 2019-01-30 | 2024-09-11 | テクニシェ ユニバーシタット ミュンヘン | がん診断用画像化剤 |
| WO2020157184A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Cancer diagnostic imaging agents |
| AU2020215086B2 (en) * | 2019-01-30 | 2025-06-05 | Technische Universität München | Cancer diagnostic imaging agents |
| KR20210153037A (ko) * | 2019-01-30 | 2021-12-16 | 테크니쉐 우니베르지테트 뮌헨 | 전립선 특이 막 항원 결합 이중 모드 방사선 추적자 및 치료법 |
| US12357711B2 (en) | 2019-01-30 | 2025-07-15 | Technische Universität München | PSMA binding dual mode radiotracer and therapeutic |
| JP2022518956A (ja) * | 2019-01-30 | 2022-03-17 | テクニシェ ユニバーシタット ミュンヘン | がん診断用画像化剤 |
| WO2020157128A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof |
| KR102850587B1 (ko) | 2019-01-30 | 2025-08-27 | 테크니쉐 우니베르지테트 뮌헨 | 전립선 특이 막 항원 결합 이중 모드 방사선 추적자 및 치료법 |
| CN112168978A (zh) * | 2019-07-03 | 2021-01-05 | 北京大学 | 一种抗体偶联药物及其药物组合物与应用 |
| EP4041213A4 (en) * | 2019-10-29 | 2023-12-27 | The Cleveland Clinic Foundation | CONTRAST AGENTS DIRECTED AGAINST PSMA |
| WO2021175147A1 (zh) * | 2020-03-02 | 2021-09-10 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| JP2023521402A (ja) * | 2020-04-09 | 2023-05-24 | ブルー アース ダイアグノスティックス リミテッド | 医薬配合物 |
| CN115484992A (zh) * | 2020-04-09 | 2022-12-16 | 蓝地诊断有限公司 | 药物制剂 |
| JP7771080B2 (ja) | 2020-04-09 | 2025-11-17 | ブルー アース ダイアグノスティックス リミテッド | 医薬配合物 |
| AU2021252191B2 (en) * | 2020-04-09 | 2024-05-02 | Blue Earth Diagnostics Ltd | Pharmaceutical formulations |
| US20210322581A1 (en) * | 2020-04-09 | 2021-10-21 | Blue Earth Diagnostics Limited | Pharmaceutical formulations |
| WO2021205185A1 (en) | 2020-04-09 | 2021-10-14 | Blue Earth Diagnostics Ltd | Pharmaceutical formulations |
| US20240277875A1 (en) * | 2020-04-09 | 2024-08-22 | Blue Earth Diagnostics Limited | Pharmaceutical formulations |
| US12427207B2 (en) * | 2020-04-09 | 2025-09-30 | Blue Earth Diagnostics Limited | Pharmaceutical formulations |
| US12036290B2 (en) | 2020-04-09 | 2024-07-16 | Blue Earth Diagnostics Limited | Pharmaceutical formulations |
| CN115484992B (en) * | 2020-04-09 | 2026-01-02 | 蓝地诊断有限公司 | Pharmaceutical preparation |
| WO2022018264A1 (en) | 2020-07-23 | 2022-01-27 | Technische Universität München | Silicon-containing ligand compounds |
| US12102696B2 (en) | 2020-09-03 | 2024-10-01 | Curium US, LLC | Radiolabeling and formulation for scale up of 64Cu-DOTATATE |
| WO2022144467A1 (en) | 2021-01-04 | 2022-07-07 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| EP4023250A1 (en) | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| CN116867520A (zh) * | 2021-01-04 | 2023-10-10 | 慕尼黑工业大学 | 双模式放射性示踪剂和治疗剂 |
| WO2022144463A1 (en) | 2021-01-04 | 2022-07-07 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| WO2022171901A1 (en) | 2021-02-15 | 2022-08-18 | Technische Universität München | Dual mode radiotracer and therapeutics |
| WO2022238553A1 (en) * | 2021-05-14 | 2022-11-17 | Technische Universität München | Radiopharmaceutical somatostatin receptor ligands and precursors thereof |
| GB202108779D0 (en) | 2021-06-18 | 2021-08-04 | Blue Earth Diagnostics Ltd | Si-at therapeutic/diagnostic compounds |
| WO2023283627A1 (en) | 2021-07-09 | 2023-01-12 | Blue Earth Diagnostics Limited | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| WO2023012282A1 (en) * | 2021-08-05 | 2023-02-09 | Technische Universität München | Ligand compounds comprising a chelating group as a bridging group |
| WO2023047138A1 (en) | 2021-09-24 | 2023-03-30 | Blue Earth Diagnostics Limited | Methods of preparation of 18f labelled silyl-fluoride compounds |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
| CN114671806A (zh) * | 2022-04-08 | 2022-06-28 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
| WO2023223050A1 (en) | 2022-05-19 | 2023-11-23 | Blue Earth Diagnostics Limited | Synthesis of fluorosilyl compounds |
| WO2024023332A1 (en) | 2022-07-29 | 2024-02-01 | Technische Universität München | Silicon-based fluoride acceptor groups for radiopharmaceuticals |
| WO2024061483A1 (en) * | 2022-09-20 | 2024-03-28 | Technische Universität München | Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy |
| EP4631959A3 (en) * | 2022-09-20 | 2025-12-17 | Technische Universität München, in Vertretung des Freistaats Bayern | Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy |
| WO2025087896A1 (en) | 2023-10-24 | 2025-05-01 | Blue Earth Therapeutics Limited | Therapeutic combination |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12453787B2 (en) | Dual mode radiotracer and-therapeutics | |
| EP3917582B1 (en) | Cancer diagnostic imaging agents | |
| CN113677400B (zh) | 结合psma的双模式放射性示踪剂及治疗剂 | |
| EP4023250A1 (en) | Dual mode radiotracer and -therapeutics | |
| US20230277698A1 (en) | Silicon-containing ligand compounds | |
| WO2022171901A1 (en) | Dual mode radiotracer and therapeutics | |
| HK40022705B (en) | Dual mode radiotracer and -therapeutics | |
| HK40022705A (en) | Dual mode radiotracer and -therapeutics | |
| EA046402B1 (ru) | Двухрежимная радиоактивная метка и радиотерапевтическое средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18743540 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2018308699 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 2018308699 Country of ref document: AU Date of ref document: 20180730 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 3071315 Country of ref document: CA Ref document number: 2020526688 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020001785 Country of ref document: BR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2018743540 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112020001785 Country of ref document: BR Free format text: - SOLICITA-SE ESCLARECIMENTOS A RESPEITO DE DOCUMENTOS ANEXADOS AS PETICOES 870200013204 (FLS.13-18) E 870200038307 (FLS.12-17), DE 23/03/2020, UMA VEZ QUE FAZEM REFERENCIA A SITUACOES DISTINTAS AO PEDIDO. |
|
| ENP | Entry into the national phase |
Ref document number: 112020001785 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200128 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 11202000725W Country of ref document: SG |
|
| WWP | Wipo information: published in national office |
Ref document number: 11202000725W Country of ref document: SG |
|
| WWR | Wipo information: refused in national office |
Ref document number: 1020247006169 Country of ref document: KR |